BackgroundUp to 3% of the general population suffers from potentially life-threatening systemic reactions after honeybee and wasp stings. Unfortunately, there are still individuals who have a convincing history of an anaphylactic event, but lack the necessary diagnostic, making difficult the decision for immunotherapy. Our aims were to evaluate the feasibility of using recombinant allergens in the Basophil activation test (BAT) for the diagnosis of Hymenoptera allergy and to develop a high-throughput diagnostic device combining the advantages of basophil activation tests with a panel of recombinant allergens: rVes v 1, rVes v 2, rVes v 3, rVes v 5, rApi m 1, rApi m 2, rApi m 3 and rApi m 5.
展开▼
机译：背景蜜蜂和黄蜂st伤后，高达3％的普通人群可能会危及生命。不幸的是，仍然存在某些令人信服的过敏反应史，但缺乏必要的诊断方法的人，这使得免疫疗法的决定变得困难。我们的目的是评估在嗜碱性粒细胞活化试验（BAT）中使用重组变应原诊断膜翅目变应性的可行性，并开发一种结合了嗜碱性粒细胞活化试验的优势和一系列重组变应原的高通量诊断设备：rVes v 1，rVes v 2，rVes v 3，rVes v 5，rapi 1，rapi 2，rapi 3和rpi 5。
展开▼
